Antibody-dependent enhancement of coronavirus
- PMID: 32920233
- PMCID: PMC7483033
- DOI: 10.1016/j.ijid.2020.09.015
Antibody-dependent enhancement of coronavirus
Abstract
Antibody-dependent enhancement (ADE) exists in several kinds of virus. It has a negative influence on antibody therapy for viral infection. This effect was first identified in dengue virus and has since also been described for coronavirus. To date, the rapid spread of the newly emerged coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), has affected over 3.8 million people across the globe. The novel coronavirus poses a great challenge and has caused a wave of panic. In this review, antibody-dependent enhancements in dengue virus and two kinds of coronavirus are summarized. Possible solutions for the effects are reported. We also speculate that ADE may exist in SARS-CoV-2.
Keywords: Antibody-dependent enhancement (ADE); Coronavirus disease 2019 (COVID-19); Middle East respiratory syndrome coronavirus (MERS-CoV); Severe acute respiratory syndrome coronavirus (SARS-CoV); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures
Similar articles
-
A perspective on potential antibody-dependent enhancement of SARS-CoV-2.Nature. 2020 Aug;584(7821):353-363. doi: 10.1038/s41586-020-2538-8. Epub 2020 Jul 13. Nature. 2020. PMID: 32659783
-
Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.Cytometry A. 2020 Jul;97(7):662-667. doi: 10.1002/cyto.a.24047. Epub 2020 Jun 7. Cytometry A. 2020. PMID: 32506725 Free PMC article. Review.
-
Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?Swiss Med Wkly. 2020 Apr 16;150:w20249. doi: 10.4414/smw.2020.20249. eCollection 2020 Apr 6. Swiss Med Wkly. 2020. PMID: 32298458 No abstract available.
-
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25. Vaccine. 2020. PMID: 32507409 Free PMC article.
-
[Strategies for vaccine development of COVID-19].Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):593-604. doi: 10.13345/j.cjb.200094. Sheng Wu Gong Cheng Xue Bao. 2020. PMID: 32347054 Review. Chinese.
Cited by
-
Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19.Curr Issues Mol Biol. 2022 Dec 21;45(1):33-50. doi: 10.3390/cimb45010003. Curr Issues Mol Biol. 2022. PMID: 36661489 Free PMC article. Review.
-
COVID-19 and plasma cells: Is there long-lived protection?Immunol Rev. 2022 Aug;309(1):40-63. doi: 10.1111/imr.13115. Epub 2022 Jul 8. Immunol Rev. 2022. PMID: 35801537 Free PMC article. Review.
-
Enhancing epitope of PEDV spike protein.Front Microbiol. 2022 Jul 22;13:933249. doi: 10.3389/fmicb.2022.933249. eCollection 2022. Front Microbiol. 2022. PMID: 35935230 Free PMC article.
-
Antibody-dependent enhancement of coronaviruses.Int J Biol Sci. 2025 Feb 3;21(4):1686-1704. doi: 10.7150/ijbs.96112. eCollection 2025. Int J Biol Sci. 2025. PMID: 39990674 Free PMC article. Review.
-
Modelling the mechanisms of antibody mixtures in viral infections: the cases of sequential homologous and heterologous dengue infections.J R Soc Interface. 2024 Oct;21(219):20240182. doi: 10.1098/rsif.2024.0182. Epub 2024 Oct 16. J R Soc Interface. 2024. PMID: 39406340
References
-
- Chan J.F.-W., Zhang A.J., Yuan S., Poon V.K.-M., Chan C.C.-S., Lee A.C.-Y., et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa325. pii: ciaa325. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous